NON-CME SYMPOSIA Locator Map

The ATS encourages Non-CME Symposia in conjunction with the International Conference. All full-conference participants are encouraged to attend these programs.

May 13-May 18, 2016 San Francisco, California conference.thoracic.org

ATS 2016 NON-CME SYMPOSIA

Sunday these burning questions during this symposium. Speakers: Welcome and Introduction - Professor Roland 6:30 to 9:30 p.m. Buhl (Chair, Germany) Hilton Union Square: Continental Are burning issues in severe asthma initiated Ballroom 5 (Ballroom Level) by small sparks? - Professor David Price Bridging the Evidence: Applying (Singapore) Case-Based Reasoning to Uncovering the hidden elements of the Improve Non-Cystic Fibrosis allergic cascade - Professor Dave Singh (UK) Bronchiectasis Care Quick-fire presentations: Role of IgE responses The program introduces an exciting learning in asthma according to disease endo/ format that simulates clinical decision making phenotypes - Professor Dave Singh (UK) and and allows you to compare your clinical Professor Chanez (France) impression and management approach to IgE in severe allergic asthma: A strong history that of the expert faculty. and new findings - Professor Pascal Chanez At the end of this learning activity, (France) participants should able to: Word from the Chair: From asthma to COPD - • Understand the impact of non-cystic fibrosis Professor Roland Buhl (Germany) bronchiectasis (NCFB) on patients’ quality- Hot topics in COPD: Why focus on of-life, disease morbidity, and mortality. exacerbations? - Professor David Price • Consider changes in NCFB management (Singapore) strategy in patients who have chronic What are we doing to reduce COPD infection with respiratory pathogens, exacerbations? - Professor Dave Singh (UK) including but not limited to P. aeruginosa. Shedding further light on COPD exacerbation • Recognize the short- and long-term prevention: New evidence - Professor Claus impact of NCFB exacerbations including Vogelmeier (Germany) its consequences on quality-of-life, future Word from the Chair: The implications of new exacerbations, hospital admissions, and evidence - Professor Roland Buhl (Germany) mortality. Time to talk: Burning questions - Chair Chairman: Timothy Aksamit, MD Rochester, MN. facilitated panel discussion Speakers: Anne O’Donnell, MD, Washington, Do we have the answers? - Professor Roland DC; James Chalmers, MD, Dundee, UK; Patrick Buhl (Germany) Flume, MD, Charleston, SC. Company: Novartis Pharma AG Expert Panelists: David Griffith, MD, Tyler, TX; Adam Hill, MD, Edinburgh, UK; Gregory Tino, MD, Philadelphia, PA; Kevin Winthrop, MD, 6:30 to 9:30 p.m. Portland, OR San Francisco Marriott Marquis: Yerba Company: Bayer Pharma AG Buena Ballroom 7 (Lower B2 Level) A Clinical Discussion on Severe Eosinophilic Asthma and Its 6:30 to 9:30 p.m. Management Park Central San Francisco: Metropolitan A review of considerations in the diagnosis Ballroom (Second Level) and management of severe eosinophilic Burning Questions in COPD and asthma. Asthma Speaker: Mario Castro, MD, MPH, FCCP, Alan A. (open to non-U.S. attendees only) and Edith L. Wolff Professor of Pulmonary and How have we progressed in COPD Critical Care Medicine, Professor of Medicine exacerbation risk reduction and what are the and Pediatrics, Washington University School of implications of the new clinical trial evidence? Medicine, St. Louis, Missouri What are the key targets in allergic asthma Company: TEVA Respiratory and how do new treatments align with different phenotypes? Join world-renowned experts discussing

Event listings current as of March 23, 2016. 3 ATS 2016 NON-CME SYMPOSIA

6:30 to 9:30 p.m. 6:30 to 9:30 p.m. San Francisco Marriott Marquis: Yerba San Francisco Marriott Marquis: Golden Buena Ballroom 9 (Lower B2 Level) Gate Ballroom B (B2 Level) Controversies in PAH: Experts Is it Idiopathic Pulmonary Explore Combination Therapy Fibrosis? Diagnostic Challenges 6:30 p.m. Registration and Buffet Dinner and Treatment 7 to 8:30 p.m. Interactive Session The process of identifying, diagnosing, and A faculty of PAH experts will explore treating idiopathic pulmonary fibrosis (IPF) developments in PAH therapy, including will be explored by a multidisciplinary panel combination therapy and recent clinical of expert faculty, including a pulmonologist, trial data. The program will also feature an radiologist, and a pathologist. The use of interactive patient scenario and allow for OFEV® (nintedanib) for the treatment of audience participation. patients with IPF will also be reviewed. Speakers: Theresa De Marco, MD, Director Speakers: Marilyn K. Glassberg, MD, Professor of of Advanced Heart Failure and Pulmonary Medicine, Surgery, and Pediatrics, University of Hypertension, Professor, University of Miami Miller School of Medicine; Mark Rumbak, California, San Francisco, School of Medicine, MD, Professor, College of Medicine, Internal San Francisco, CA; Nicholas Hill, MD, Chief, Medicine University of South Florida; Sudhakar Pulmonary, Critical Care and Sleep Division, Pipavath, MD, Associate Professor, Radiology, Professor, Tufts University School of Medicine, University of Washington; Kirk Jones, Professor, Boston, MA; Rajan Saggar, MD, Assistant Clinical Pathology, UCSF School of Medicine Professor of Medicine, Pulmonary & Critical Care, Company: Boehringer Ingelheim University of California, Los Angeles Medical Pharmaceuticals, Inc. Center, Los Angeles, CA Company: Gilead Sciences, Inc. 6:30 to 9:30 p.m. Hilton Union Square: Continental 6:30 to 9:30 p.m. Ballroom 4 (Ballroom Level) Hilton Union Square: Continental Evolving Science in the Ballroom 6 (Ballroom Level) Management of COPD COPD Treatment Options This non-CME dinner symposium will offer Available Via Ellipta® Inhaler novel insights into the latest research in This interactive dinner program will provide inhaled respiratory medication in COPD. an overview of COPD treatment options Speakers: Bartolome Celli (Chair), USA; Klaus F. available via the Ellipta® inhaler. The Rabe, Germany; Leonardo M. Fabbri, Italy; Gary presentation will address the rationale for T. Ferguson, USA; Fernando J. Martinez, USA combination therapy in the treatment of Company: AstraZeneca Pharmaceuticals, Inc. COPD and will include clinical trials data, and important safety information as well as a demonstration of the Ellipta® inhaler and examination of the device characteristics and features. Speakers: Deborah Long, MD, FCCP, US Medical Affairs Lead, GSK, Research Triangle Park, NC; Neil C. Barnes, MD, Medical Head, Global Respiratory Franchise, GSK, Uxbridge, UK Company: GlaxoSmithKline

4 Event listings current as of March 23, 2016. You are invited to an evening symposium Introducing a New Treatment Option for PAH: A Case-based Discussion Sunday, May 15, 2016 6:30 – 7:00 PM Registration and Dinner 7:00 – 8:30 PM Symposium

Faculty InterContinental San Francisco Vallerie McLaughlin, MD, Gran d Ballroom, 3rd Floor

Program Chair 888 How ard Street University of Michigan San Francisco, California Health System Ann Arbor, Michigan T EE T STR RKE T E FO E U RTH STR F IF N STR Nick Kim, MD TH STR SO IS ET E M E ET EE T A STR N Moscone IN University of California, M Center West

InterContinental San Francisco ET San Diego E D STR 888 Howard Street R WA O La Jolla, California H

ET F E IF ET TH STR E A STR N A STR EE ENTI M T M T ATO LE E Victor Tapson, MD N C E M STR O ET LS E FO XTH S D STR R EY S Cedars-Sinai Medical Center PL TR WA I O H E H S Los Angeles, California ET

This promotional program is sponsored by Actelion Pharmaceuticals US, Inc. Dinner will not be provided to physicians and other healthcare professionals licensed in Vermont or other states where gifts and meals are prohibited. Dinner provided to physicians will be subject to reporting under Federal law. We regret that spouses and other guests may not be accommodated. An Industry-Organized Symposium at the ATS 2016 International Conference. A non-CME educational program sponsored by Actelion Pharmaceuticals US, Inc. open to all ATS 2016 International Conference attendees.

ATS 2016 NON-CME SYMPOSIA

6:30 to 9:30 p.m. 6:30 to 9:30 p.m. Hilton Union Square: Imperial Ballroom (Ballroom Level) Sarcoidosis: A Multidisciplinary Approach to Diagnosis and Management (open to non-U.S. attendees only) The current state of sarcoidosis diagnosis and management will be discussed. Topics will include: • Introduction to Sarcoidosis, Marc A. Judson, MD • Cardiac Sarcoidosis, TBD San Francisco Marriott Marquis: Golden • Neurosarcoidosis, Jinny Tavee, MD Gate Ballroom A (B2 Level) • Ocular Sarcoidosis, James Rosenbaum, MD Expert Perspectives: Idiopathic • Pulmonary Sarcoidosis, Robert P. Baughman, Pulmonary Fibrosis (IPF) Dinner MD Symposium • Therapy for Symptomatic Sarcoidosis, Join three esteemed IPF experts as they Robert P. Baughman, MD share their perspectives on the diagnosis and Dinner will be provided. management of IPF at this dinner symposium. Company: Mallinckrodt Pharmaceuticals These IPF experts will engage participants in a series of presentations on topics such as making an early diagnosis, the efficacy and 8:30 to 10:30 p.m. Dessert Symposium safety profile of an FDA-approved therapy, San Francisco Marriott Marquis: and effectively managing the IPF patient. Mezzanine (Second Level) Company: Genentech, Inc. Joint Presentation on Seasonal Allergic Rhinitis and Maintenance Treatment of Asthma 6:30 to 9:30 p.m. Meda Pharmaceuticals will host a joint InterContinental San Francisco: Grand presentation on Seasonal Allergic Rhinitis Ballroom (Third Level) and maintenance treatment of Asthma. A Introducing a New Treatment donation of $75 will be made to The ATS Option for PAH: A Case-based Foundation for each registered ATS attendee Discussion attending this Non-CME Symposium. The science behind pulmonary arterial Speakers: William E. Berger, MD, MBA, hypertension (PAH) continues to evolve. University of California Irvine, Mission Viejo, CA; This interactive, case-based symposium will Randall W. Brown, MD, MPH, AE-C, University of feature a panel of experts who will introduce Michigan, Ann Arbor, MI; Bradley Chipps, MD, a new option for the treatment of patients Capital Allergy & Respiratory Disease Center, with PAH. Sacramento, CA; LeRoy Graham, MD, Bridge Dinner will be provided. Dinner will not be Atlanta Medical Group, Atlanta, GA; Michael provided to physicians and other healthcare G. Marcus, MD, Maimonides Medical Center, professionals licensed in Vermont or other Brooklyn, NY; Kevin R. Murphy, MD, Boys Town states where gifts and meals are prohibited. National Research Hospital, Omaha, NE; David Speakers: Vallerie McLaughlin, MD, Program P. Skoner, MD, Allegheny General Hospital, Chair, University of Michigan Health System, Pittsburgh, PA; Maeve O’Connor, MD, Allergy Ann Arbor, Michigan; Nick Kim, MD, University of Asthma & Immunology Relief, Charlotte, NC California, San Diego, La Jolla, California; Victor Company: MEDA Pharmaceuticals, Inc. Tapson, MD, Cedars-Sinai Medical Center, Los Angeles, California Company: Actelion Pharmaceuticals US, Inc.

6 Event listings current as of March 23, 2016. A MECC-Organized Symposium at the ATS 2016 International Conference IPF CASE DISCUSSIONS: WHAT HAVE WE LEARNED AFTER 18 MONTHS WITH PIRFENIDONE AND NINTEDANIB?

5.17.16 | 6:30-9:30 PM Continental Ballroom 6 | Hilton Union Square

FACULTY PAUL W. NOBLE, MD (CHAIR) LUCA RICHELDI, MD, PhD ALISON G. WILCOX, MD, FSCCT

AGENDA 6:30–6:45 Pm Gather and Dinner

6:45–9:00 Pm Highly Interactive Case Discussions

9:00 pm meet the Experts: Let’s Talk IpF Faculty will host a special small 5:1 table discussion with interested learners to discuss any specific cases and questions related to IPF. Register early! This opportunity will only be available to a total of 15 learners.

Learners will use iPads during this highly interactive activity to focus on how the multidisciplinary team works together to manage patients with IPF.

A non-CmE educational program sponsored by The France Foundation and supported by Grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech open to all ATS 2016 International Conference attendees

Sponsored by

There is no fee for this educational activity. Seating will be provided on a first-come, first-served basis. ATS 2016 NON-CME SYMPOSIA

6:30 to 9:30 p.m. Tuesday San Francisco Marriott Marquis: Yerba Buena Ballroom 9 (Lower B2 Level) 6:30 to 9:30 p.m. Fixed Dose LAMA/LABA Inhalers San Francisco Marriott Marquis: Golden in COPD: What the Trials Tell Us Gate Ballroom A (B2 Level) Evidence increasingly supports a prominent Do You Know Your Asthma role for fixed-dose combinations of long- Patients’ Phenotypes? acting muscarinic antagonists and long-acting (open to non-U.S. attendees only) ß2-agonists (LAMA/LABA) in the management Chaired by Professor Eric D. Bateman, an of patients with COPD. This interactive internationally renowned faculty will discuss symposium will present the latest efficacy the impact of asthma pathophysiology on and safety data of new and emerging fixed- approaches to management, barriers to dose LAMA/LABA combinations, including improving control of symptomatic asthma, application to specific patient case scenarios. and the evidence for using anticholinergic Speaker: Chair: Richard H Casaburi, MD, MEng, PhD bronchodilator therapy for asthma. Company: The France Foundation Attendance at this symposium is for non-US (supported by a grant from Boehringer healthcare professionals only. Ingelheim Pharmaceuticals, Inc.) Speakers: • Professor Eric D Bateman (South Africa) [Chair] • Professor Christian Taube (the Netherlands) 6:30 to 9:30 p.m. • Professor Huib Kerstjens (the Netherlands) San Francisco Marriott Marquis: Golden • Professor William Busse (United States) Gate Ballroom B (B2 Level) Company: Boehringer Ingelheim Pharma Holding Court in PAH GmbH & Co. KG Experience the drama and excitement of Holding Court in PAH, as some of the most challenging treatment issues are argued by leading experts 6:30 to 9:30 p.m. in pulmonary hypertension. With the honorable San Francisco Marriott Marquis: Yerba judge Lewis Rubin, MD presiding, you the jury will Buena Ballroom 7 (Lower B2 Level) deliberate the evidence, then cast your vote for a Evolving Perspectives in Asthma winner. Register at www.pah.tv. Heterogeneity: The Role of Speakers: (Chair) Lewis J. Rubin, MD, APMC , Eosinophils Professor of Medicine, Pulmonary and Critical This non-CME dinner symposium will explore Care Division, Director, PAH Program UC San current and emerging scientific concepts Diego School of Medicine, San Diego, CA. Faculty: in asthma heterogeneity and the role of Richard Channick, MD, Director, Pulmonary eosinophils in uncontrolled asthma. Hypertension and Thromboendarterectomy Speakers: Bartolome Celli, USA (Chair) Program, Massachusetts General Hospital, Boston, 1. Unmet Need in Uncontrolled Asthma and MA; Martha Kingman Liberty, FNP-C, DNP, Nurse Barriers to Improved Outcomes (~30 mins) Practitioner, Pulmonary Services, Heart & Lung Mark FitzGerald (Canada) Center, UT Southwestern Medical Center, Dallas, 2. Cellular and Molecular Endotypes and TX; Richard A. Krasuski, MD, FACC, FAHA, FESC, Phenotypes in Uncontrolled Asthma (~30 Professor of Medicine and Pediatrics, Director of the mins) Parameswaran Nair (Canada) Adult Congenital Heart Disease Center, Director of 3. The Biology and Role of Eosinophils in Hemodynamic Research, Duke University Medical Uncontrolled Asthma (~30 mins) Andrew Center, Durham, NC; Vallerie McLaughlin, MD; Kim Menzies-Gow (UK) A. Eagle, MD, Endowed Professor of Cardiovascular 4. Understanding Disease Heterogeneity and Medicine, Dept. of Internal Medicine/ the Importance of Biomarkers (~30 mins) Rey Cardiovascular Medicine, University of Michigan, Panettieri (US) Ann Arbor, MI; Ioana Preston, MD, Associate Company: AstraZeneca Pharmaceuticals, Inc. Professor of Medicine, Pulmonary Function Lab Director, Director, Pulmonary Hypertension Center, Tufts University School of Medicine, Boston, MA;

8 Event listings current as of March 23, 2016. ATS 2016 NON-CME SYMPOSIA

Rajan Saggar, MD, Assistant Clinical Professor highly interactive activity will focus on how of Medicine, Pulmonary & Critical Care, Director the multidisciplinary team works together of the Medical Intensive Care Unit, Heart-Lung to manage patients with IPF. IPF experts Transplant & Pulmonary Hypertension Programs, will dissect and debate cases that illustrate Ronald Reagan UCLA Medical Center, Los Angeles, clinical quandaries not addressed by recent CA; Sean Studer, MD, MSc, Chief of Medicine, NYU- clinical studies. This interactive learning Woodhull Medical Center, New York, NY; Victor format will enhance the learners’ ability to Tapson, MD, Professor of Pulmonary and Critical apply knowledge and expert experience to Care Medicine, Cedars-Sinai Medical Center, Los clinical practice. Participants can register for Angeles, CA a select few spots to meet in small groups Company: PAH.TV (supported by an with the faculty, immediately following the unrestricted educational grant from Actelion symposium, to discuss their own clinical cases. Pharmaceuticals) Speakers: Chair - Paul W. Noble, MD, Chair, Department of Medicine, Director, Women’s Guild Lung Institute, Cedars-Sinai Medical 6:30 to 9:30 p.m. Center, Los Angeles, California; Alison G. Wilcox, Hilton Union Square: Continental MD, FSCCT, Associate Professor of Radiology and Ballroom 6 (Ballroom Level) Internal Medicine, Section Chief, Cardiothoracic IPF Case Discussions: What Have Imaging, Medical Director, Imaging, Keck We Learned After 18 Months with Hospital of USC, Keck Medical Center of USC, Pirfenidone and Nintedanib? Los Angeles, CA; Professor Luca Richeldi, MD, Supported by an independent grant, this PhD, Professor of Respiratory Medicine, Chair 01.ats locator map-copd(1/2).qxp_Layout 1 3/17/16 2:22 PM Page 2